2022 World Conference on Lung Cancer (ePosters)-EP08.01-063. Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%

EP08.01-063. Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%

Back to course

Pdf Summary

This poster presentation explores the comparative effectiveness of chemoimmunotherapy versus immunotherapy alone as first-line treatment for patients with advanced non-small-cell lung cancer (aNSCLC) and high tumor expression of PD-(L)1. The study aimed to determine whether chemoimmunotherapy provides a survival advantage and if it is warranted considering the additional side effects associated with combination therapy. <br /><br />The study analyzed data from 3086 subjects who met inclusion criteria, with 32% receiving chemoimmunotherapy and 68% receiving immunotherapy alone. The baseline characteristics of the patients were well balanced post-weighting. The results showed that chemoimmunotherapy was not associated with a survival advantage over immunotherapy alone during the entire follow-up period. However, it did demonstrate a survival benefit during the first 6 months. <br /><br />In subgroup analysis of patients with a PD-L1 score of 90%, chemoimmunotherapy also did not provide an overall survival advantage compared to immunotherapy alone. However, it did show a survival benefit during the first 12 months. <br /><br />The findings suggest that providers should carefully consider the short-term benefits of chemoimmunotherapy versus the long-term equivalence of immunotherapy alone for patients with aNSCLC and high PD-L1 expression. Further head-to-head efficacy trials are needed to provide more evidence on the comparative effectiveness of these treatments.<br /><br />In conclusion, this study found that chemoimmunotherapy was not associated with an overall survival advantage over immunotherapy alone for patients with aNSCLC and high PD-L1 expression. However, it did show a survival benefit in the first 6 months and in the first 12 months for patients with a PD-L1 score of 90%. Providers should carefully weigh the short-term benefits of chemoimmunotherapy against the long-term equivalence of immunotherapy alone when making treatment decisions for these patients.

Asset Subtitle

Mohsin Shah

Meta Tag

Speaker Mohsin Shah

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

comparative effectiveness

chemoimmunotherapy

immunotherapy

first-line treatment

non-small-cell lung cancer

PD-(L)1

survival advantage

side effects

baseline characteristics

overall survival